Director/PDMR Shareholding
Peter Soelkner, a Non-Executive Director and Vice Chair of Oxford Biomedica PLC, purchased 1,672.27 ordinary shares on the London Stock Exchange for EUR 5.959 per share, totaling EUR 9,965.86. Following this transaction, Mr. Soelkner now holds 3,338.94 shares, representing 0.00275% of the Company. This purchase was disclosed in accordance with EU Market Abuse Regulation requirements.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK – 28 September 2026: OXB (LSE: OXB) (the “Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that Peter Soelkner, a Non-Executive Director and Vice Chair of the Company, has purchased 1,672.27 ordinary shares of 50p each (“Ordinary Shares”) in the Company on 28 September 2026 on the London Stock Exchange at a price of EUR 5.959. Following this purchase, Peter Soelkner holds 3,338.94 shares representing 0.00275% of the Company.
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Peter Soelkner | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 28-September-2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Purchase of shares | ||||
| e) | Place of the transaction | London Stock Exchange (XLON) | ||||
| f) | Currency | EUR – Euro | ||||
| g) | Price(s) and volumes(s) |
.27 | ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 1672.27 EUR 5.959 EUR 9,965.86 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.